Mereo BioPharma Group plc (MAH0) - Net Assets
Based on the latest financial reports, Mereo BioPharma Group plc (MAH0) has net assets worth €46.60 Million EUR (≈ $54.48 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€53.60 Million ≈ $62.67 Million USD) and total liabilities (€7.00 Million ≈ $8.19 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Mereo BioPharma Group plc (MAH0) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €46.60 Million |
| % of Total Assets | 86.93% |
| Annual Growth Rate | -3.23% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 49.81 |
Mereo BioPharma Group plc - Net Assets Trend (2016–2024)
This chart illustrates how Mereo BioPharma Group plc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Mereo BioPharma Group plc for the complete picture of this company's asset base.
Annual Net Assets for Mereo BioPharma Group plc (2016–2024)
The table below shows the annual net assets of Mereo BioPharma Group plc from 2016 to 2024. For live valuation and market cap data, see Mereo BioPharma Group plc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €60.97 Million ≈ $71.28 Million |
+20.64% |
| 2023-12-31 | €50.54 Million ≈ $59.08 Million |
-18.31% |
| 2022-12-31 | €61.87 Million ≈ $72.33 Million |
-29.70% |
| 2021-12-31 | €88.00 Million ≈ $102.88 Million |
+687.82% |
| 2020-12-31 | €-14.97 Million ≈ $-17.50 Million |
-137.19% |
| 2019-12-31 | €40.26 Million ≈ $47.06 Million |
+22.84% |
| 2018-12-31 | €32.77 Million ≈ $38.31 Million |
-47.55% |
| 2017-12-31 | €62.48 Million ≈ $73.05 Million |
-21.16% |
| 2016-12-31 | €79.26 Million ≈ $92.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mereo BioPharma Group plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42230375900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €523.85 Million | 859.21% |
| Total Equity | €60.97 Million | 100.00% |
Mereo BioPharma Group plc Competitors by Market Cap
The table below lists competitors of Mereo BioPharma Group plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MoneyHero Limited Class A Ordinary Shares
NASDAQ:MNY
|
$40.20 Million |
|
JP Morgan Global Growth & Income PLC
LSE:JGGI
|
$40.20 Million |
|
S H L Telemedicine Ltd
SW:SHLTN
|
$40.21 Million |
|
Manomay Tex India Limited
NSE:MANOMAY
|
$40.23 Million |
|
Jeil Technos Co.Ltd
KQ:038010
|
$40.18 Million |
|
Beammwave AB B
ST:BEAMMW-B
|
$40.17 Million |
|
Sumi Indo Kabel Tbk
JK:IKBI
|
$40.16 Million |
|
Lohakit Metal Public Company Limited
BK:LHK
|
$40.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mereo BioPharma Group plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 50,537,000 to 60,969,000, a change of 10,432,000 (20.6%).
- Net loss of 43,253,000 reduced equity.
- New share issuances of 47,000,000 increased equity.
- Other factors increased equity by 6,685,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-43.25 Million | -70.94% |
| Share Issuances | €47.00 Million | +77.09% |
| Other Changes | €6.68 Million | +10.96% |
| Total Change | €- | 20.64% |
Book Value vs Market Value Analysis
This analysis compares Mereo BioPharma Group plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.25x to 2.75x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.88 | €0.22 | x |
| 2018-12-31 | €0.46 | €0.22 | x |
| 2019-12-31 | €0.41 | €0.22 | x |
| 2020-12-31 | €-0.04 | €0.22 | x |
| 2021-12-31 | €0.15 | €0.22 | x |
| 2022-12-31 | €0.10 | €0.22 | x |
| 2023-12-31 | €0.07 | €0.22 | x |
| 2024-12-31 | €0.08 | €0.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mereo BioPharma Group plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -70.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.25x
- Recent ROE (-70.94%) is below the historical average (-50.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -35.82% | 0.00% | 0.00x | 1.09x | €-36.32 Million |
| 2017 | -62.09% | 0.00% | 0.00x | 1.54x | €-45.05 Million |
| 2018 | -97.74% | 0.00% | 0.00x | 2.05x | €-35.31 Million |
| 2019 | -86.56% | 0.00% | 0.00x | 2.15x | €-38.87 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | €-162.13 Million |
| 2021 | 14.46% | 34.90% | 0.29x | 1.44x | €3.92 Million |
| 2022 | -55.27% | 0.00% | 0.00x | 1.42x | €-40.38 Million |
| 2023 | -58.31% | -294.66% | 0.15x | 1.32x | €-34.52 Million |
| 2024 | -70.94% | 0.00% | 0.00x | 1.25x | €-49.35 Million |
Industry Comparison
This section compares Mereo BioPharma Group plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $979,793,893
- Average return on equity (ROE) among peers: -18.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mereo BioPharma Group plc (MAH0) | €46.60 Million | -35.82% | 0.15x | $40.19 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $2.05 Billion |
| BioNTech SE (22UA) | $1.37 Billion | 1.11% | 0.69x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.98 Billion | -7.02% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.67 Billion | -12.59% | 0.28x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more